Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia

Roberto Carlos Agís-Balboa1,4,†, Paulo S Pinheiro2,3,5,†,8,‡, Nelson Rebola2,3,†,8,‡, Cemil Kerimoglu1,4, Eva Benito1, Michael Gertig1, Sanaz Bahari-Javan4, Gaurav Jain4, Susanne Burkhardt1, Ivana Delalle5, Alexander Jatzko6, Markus Dettenhofer7,‡, Patricia A Zunszain8, Andrea Schmitt9,10, Peter Falkai9, Julius C Pape11, Elisabeth B Binder11, Christophe Mulle2,3, Andre Fischer1,4,†,§ & Farahnaz Sananbenesi1,12,**,†

Abstract

Age-associated memory decline is due to variable combinations of genetic and environmental risk factors. How these risk factors interact to drive disease onset is currently unknown. Here we begin to elucidate the mechanisms by which post-traumatic stress disorder (PTSD) at a young age contributes to an increased risk to develop dementia at old age. We show that the actin nucleator Formin 2 (Fmn2) is deregulated in PTSD and in Alzheimer’s disease (AD) patients. Young mice lacking the Fmn2 gene exhibit PTSD-like phenotypes and corresponding impairments of synaptic plasticity, while the consolidation of new memories is unaffected. However, Fmn2 mutant mice develop accelerated age-associated memory decline that is further increased in the presence of additional risk factors and is mechanistically linked to a loss of transcriptional homeostasis. In conclusion, our data present a new approach to explore the connection between AD risk factors across life span and provide mechanistic insight to the processes by which neuropsychiatric diseases at a young age affect the risk for developing dementia.

Keywords: aging; Alzheimer’s disease; Formin 2; HDAC inhibitor; post-traumatic stress disorder

Subject Categories: Molecular Biology of Disease; Neuroscience

DOI: 10.15252/embj.201796821 | Received 25 February 2017 | Revised 23 June 2017 | Accepted 27 June 2017 | Published online 2 August 2017

The EMBO Journal (2017) 36: 2815–2828

See also: J Gräff (October 2017)

Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disorder causing a huge emotional and economical burden to our societies. The vast majority of AD cases are sporadic and arise on the background of variable genetic and environmental risk factors. There is substantial evidence that pathological changes occur years before the onset of clinical symptoms (Bateman et al., 2012). To elucidate how the different risk factors contribute to disease onset is therefore of utmost importance. The starting point of this study is epidemiological data indicating that individuals suffering from neuropsychiatric diseases such post-traumatic stress disorder (PTSD) at a young age have an increased risk of developing AD in old age (Yaffe et al., 2010; Burri et al., 2013; Weiner et al., 2013; Stilling et al., 2014a). PTSD develops in response to a traumatic event when normal psychological defense mechanisms fail. Individuals that suffer from PTSD are deficient in learning that a stimulus associated with an adverse event no longer presents a threat, a process that requires cognitive flexibility and extinction learning (Goswami et al., 2013). Memory extinction can be analyzed in rodents using the well-established fear conditioning paradigm. This paradigm represents a specific form of learning that underlies the reduction of previously acquired fear memories (Myers & Davis, 2007).

1 Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
2 Interdisciplinary Institute for Neuroscience, University of Bordeaux, Bordeaux, France
3 CNRS UMR 5297, Bordeaux, France
4 Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
5 Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA
6 Department of Psychiatriometrics, Westpfalzklinikum-Kaiserslautern, Teaching Hospital, University of Mainz, Mainz, Germany
7 CEITEC – Central European Institute of Technology, Masaryk University, Brno, Czech Republic
8 Stress, Psychiatry and Immunology Laboratory, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
9 Department of Psychiatry and Psychotherapy, LMU Munich, Munich, Germany
10 Laboratory of Neuroscience (LUM27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil
11 Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
12 Research Group for Genome Dynamics in Brain Diseases, Göttingen, Germany

*Corresponding author. Tel: +49 551 3961211; E-mail: andre.fischer@dzne.de
**Corresponding author. Tel: +49 551 39 61211; Fax: +49 3961212; E-mail: farahnaz.sananbenesi@dzne.de
† These authors contributed equally to this work
‡ Present address: Psychiatric Diseases Research Group, Galicia Sur Health Research Institute, Sergas, Cibersam, Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain
§ Present address: CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
** Present address: CNS-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
*** Present address: The EMBO Journal Vol 36 | No 19 | 2017 2815

© 2017 The Authors. Published under the terms of the CC BY 4.0 license
2002; Lattal et al., 2006; Sananbenesi et al., 2007; Fischer & Tsai, 2008; Radulovic & Tronson, 2010). Although impaired fear extinction in rodents does not recapitulate the complex phenotypes observed in humans suffering from PTSD, it is suitable to study the mechanisms that underlie increased susceptibility to PTSD. Thus, we reasoned that a promising strategy to elucidate the molecular mechanisms that link PTSD at a young age to an increased risk for age-associated memory decline and AD would be to screen for animal models that exhibit (i) impaired fear extinction at young age, while consolidation of new memories is still intact, but (ii) develop accelerated memory impairment in the presence of additional AD risk factors. By this, we identified the *Formin 2* (*Fmn2*) gene. FMN2 is best known for its role in regulating actin dynamics (Schuh, 2011) and was previously detected in a screen for genes that are deregulated in the aging mouse hippocampus (Peleg et al., 2010). In addition, FMN2 has been linked to synapse formation and depletion mutations of the *Fmn2* gene are associated with intellectual disability, pointing to a role for *Fmn2* in memory function in mice and humans (Peleg et al., 2010; Almuqbil et al., 2013; Law et al., 2014). Here we show that loss of *Fmn2* affects plasticity at the mossy fiber-CA3 synapse and causes impaired fear extinction in young mice. We furthermore show that *Fmn2* expression is decreased in PTSD patients and in post-mortem brain samples from AD patients. Loss of *Fmn2* accelerates age-associated memory decline, which is further accelerated in the presence of amyloid pathology and is accompanied by deregulation of hippocampal gene expression. While the mechanisms that link reduced FMN2 levels to aberrant gene expression are likely to be multifactorial, we provide evidence that FMN2-dependent synaptic actin dynamics signal via the ERK1/2 pathway to drive Elk1 and SP1-dependent gene expression. Of note, memory impairment in all employed models is ameliorated after oral administration of the HDAC inhibitor Vorinostat. In sum, our data represent a new approach to explore the cross-talk between AD risk factors across life span and provide evidence that loss of transcriptional plasticity is a key event down-stream of AD risk factor exposure.

**Results**

**Loss of FMN2 leads to impaired fear extinction in young mice**

We started our analysis by employing animal models for age-associated memory decline and tested whether extinction phenotypes precede the impairment of memory consolidation. We decided to test APPPS1-21 and 5xFAD mice, two well-established mouse models for amyloid deposition and age-associated memory impairment that are linked to familiar Alzheimer’s disease (Radde et al., 2006; Ohno et al., 2007; Govindarajan et al., 2013). In addition, we employed *Fmn2* knockout (*Fmn2*\(^{−/−}\)) mice. Although the role of FMN2 in the adult brain is not well understood, FMN2 has recently been linked to age-related memory impairment in mice (Peleg et al., 2010) and is associated with cognitive dysfunction in humans (Almuqbil et al., 2013; Law et al., 2014). Mice from all experimental groups were subjected to contextual fear conditioning training at 3 month of age. Freezing behavior, indicative of associative memory consolidation, was similar in all mutant mice when compared to the corresponding control groups during a memory test performed 24 h later (Fig 1A). To test extinction of fear memory, animals were re-exposed to the conditioning context on consecutive days in the absence of the foot shock, a procedure that induces extinction learning and leads to the reduction in the aversive freezing response (Sananbenesi et al., 2007; Tronson et al., 2012). Fear extinction was similar in APPPS1-21 (Fig 1B) and 5xFAD mice (Fig 1C) when compared to the corresponding control groups. In contrast, fear extinction learning was impaired in *Fmn2*\(^{−/−}\) mice (Fig 1D). Next we confirmed that all three lines of mutant mice exhibit impaired consolidation of new memories already at 8 months of age (Fig 1E), while wild-type mice were impaired only at 16 months of age (Fig 1F). These data indicate that *Fmn2*\(^{−/−}\) mice develop deficits in fear extinction that precede impairment of memory consolidation. However, the possibility remained that the employed fear conditioning protocol does not allow for the detection of very mild memory impairments. Therefore, we also subjected *Fmn2*\(^{−/−}\) mice to a milder fear conditioning protocol (Kerimoglu et al., 2013). In line with our initial observation, *Fmn2*\(^{−/−}\) mice did not exhibit memory impairment at 3 months of age (see Appendix Fig S1). In line with these data, 3-month-old *Fmn2*\(^{−/−}\) mice were able to acquire spatial reference memory in the Morris water maze test similar to wild-type mice (Fig EV1A and B). Reversal learning was, however, impaired (Fig EV1C and D), which supports the view that loss of *Fmn2* in young mice does not affect the consolidation of new memories but is required for changing responses to existing memories. Taking together, these data support the view that the analysis of FMN2 would be a good starting point to investigate the mechanisms by which neuropsychiatric diseases at young age contribute to an increased risk for age-associative memory decline. Before continuing our analysis, however, we sought to provide further evidence for this hypothesis. To this end, we tested *Fmn2* expression in blood samples from PTSD patients via qPCR. We observed a significant reduction in *Fmn2* expression in PTSD patients when compared to age-matched control individuals (Zieker et al., 2007; Fig 1G). Although care has to be taken when interpreting data obtained from blood in the context of brain diseases, there is increasing evidence that adverse life events can induce long-lasting changes in the expression of specific genes and that such changes in gene expression are detected in various cell types such as cells obtained from blood or saliva (Smith et al., 2015). Thus, the analysis of gene expression, for example, in blood, is viewed as a suitable approach to identify biomarker and surrogate marker for brain diseases (Rao et al., 2013; Ciobanu et al., 2016; Schmitt et al., 2016). The fact that *Fmn2* levels are altered in blood samples from PTSD patients therefore indicates that exposure to PTSD-inducing events may similarly alter *Fmn2* levels in the brain. Since we do not have access to suitable post-mortem tissue from PTSD patients, this hypothesis remains to be tested. However, PTSD and other neuropsychiatric diseases have been linked to altered glucocorticoid signaling (Du & Pang, 2015; Kim et al., 2015). It is therefore interesting that *Fmn2* expression was decreased in human neuronal progenitor cells subjected to acute or chronic dexamethasone treatment, a synthetic glucocorticoid that can have detrimental effects on neuronal function and cognitive abilities (Crochembre et al., 2005; Tongjaroenbuangam et al., 2013; Feng et al., 2015; Lanshakov et al., 2016; Fig 1H). We also observed decreased *Fmn2* expression in post-mortem human brain samples (hippocampus) from AD patients when compared to age-matched control individuals (Fig 1I).
Encouraged by these observations, we decided to study the role of FMN2 in the adult brain in greater detail. 

**Fmn2** was highly expressed in mouse and human hippocampal neurons (Fig 2A). In line with these findings, robust FMN2 protein levels were observed in the mouse and human hippocampus (Fig 2B). The specificity of the FMN2 antibody employed for immunoblotting was confirmed using corresponding hippocampal tissue from *Fmn2*−/− mice as negative control (Fig 2C). Since we could not identify a suitable antibody to reliably detect FMN2 via immunostaining, we generated a negative control (Fig 2C). Since we could not identify a suitable antibody to reliably detect FMN2 via immunostaining, we generated a negative control (Fig 2C). Since we could not identify a suitable antibody to reliably detect FMN2 via immunostaining, we generated a negative control (Fig 2C). Since we could not identify a suitable antibody to reliably detect FMN2 via immunostaining, we generated a negative control (Fig 2C).

**Figure 1.** Impaired fear extinction precedes memory decline in *Fmn2* mutant mice.

- **A** Freezing behavior tested 24 h after training was similar in 3-month-old APPPS1-21, 5xFAD, and *Fmn2*−/− mice when compared to corresponding control groups (n = 10/group).
- **B** Fear extinction in 3-month-old APPPS1 mice is similar to a non-transgenic control group (n = 9/group).
- **C** Fear extinction in 3-month-old 5xFAD mice is similar to a non-transgenic control group (n = 9/group).
- **D** Extinction learning in the contextual fear conditioning paradigm is impaired in *Fmn2*−/− mice (n = 9/group, ***P < 0.001, F = 21.77, two-way RM ANOVA).
- **E** Freezing behavior was tested 24 h after training in 8-month-old APPPS1-21, 5xFAD, and *Fmn2*−/− mice. A significant impairment in associative memory was observed when comparing APPPS1 mice (n = 10) to a corresponding control group (n = 8, **P < 0.01, t-test), when comparing 5xFAD mice (n = 10) to a corresponding control group (n = 8, **P = 0.01, t-test), and when comparing *Fmn2*−/− mice (n = 10) to corresponding *Fmn2*+/+ wild-type mice (n = 10, ***P < 0.0001, t-test).
- **F** Freezing was analyzed in 3- (n = 11), 12- (n = 9), and 21- (n = 8)-month-old male wild-type mice. A significant impairment (**P < 0.001, t-test) was observed in 16-month-old animals when compared to either 3- or 12-month-old animals.
- **G** *Fmn2* expression measured in blood samples via qPCR was reduced in PTSD patients (n = 7, *P = 0.0361, t-test).
- **H** *Fmn2* mRNA expression is decreased after dexamethasone treatments in human hippocampal progenitor cells (HPCs) during neuronal proliferation (3 days) and differentiation (10 days) (**P < 0.01, one-way ANOVA followed by Bonferroni correction). *Fmn2* expression was decreased in control (n = 9) when compared to age-matched controls (n = 8).

Data information: Error bars indicated SEM.

These data suggest that the susceptibility to develop PTSD-like phenotypes observed in 3-month-old *Fmn2*−/− mice involves compromised plasticity at the hippocampal mossy fiber-CA3 synapse. Thus, we analyzed the electrophysiological properties of mossy fiber synapses in *Fmn2*−/− mice at 3 months of age. We found that long-term potentiation (LTP) and long-term depression (LTD) were unaffected (Fig 2F and G). However, *Fmn2*−/− mice exhibited impaired depotentiation, a well-established phenomenon by which mossy fiber-CA3 LTP can be reversed using long trains of low-frequency stimulation that has been discussed as a molecular correlate of extinction processes (Hong et al, 2009; Kim et al, 2009; Fig 2H).

Although gross brain morphology, motor coordination, explorative behavior, and basal anxiety were similar when comparing 3-month-old *Fmn2*−/− mice and control littermates (Fig EV2), our *Fmn2*−/− mice constitutively lack FMN2. Thus, the possibility remained that the observed fear extinction phenotype could in part be due to subtle development abnormalities and in addition may not be specific to hippocampal function. To test for this possibility, we employed an RNAi approach and found that RNAi-mediated decrease in *Fmn2* in the hippocampus impairs fear extinction, but has no effect on the consolidation of new memories. To this end, we first confirmed that intra-hippocampal injection of an siRNA against *Fmn2* reduces *Fmn2* mRNA and protein levels when compared to the scramble control group.
Next we subjected mice to contextual fear conditioning and injected siRNA or scrambled control RNA for 3 days (every 12 h) before animals were subjected to fear extinction (Fig 3D). Injections were continued during extinction trials 1-3. Extinction was significantly impaired when comparing the siRNA versus the scramble control RNA-injected mice (Fig 3E). When animals were allowed to rest for 6 days after extinction trial 4 and did not receive further injections, normal extinction behavior was observed when mice were subsequently subjected to further extinction training. These data indicate that siRNA-mediated impairment of extinction is not due to unspecific effects of the injection procedure (Fig 3D and E). Finally, we show that siRNA-mediated knockdown of \textit{Fmn2} does not affect the acquisition of contextual fear memories (Fig 3F).

In conclusion, these data indicate that loss of FMN2 leads to impaired fear extinction which is accompanied by mild deficits in neuronal plasticity that mimic the behavioral alterations.

Loss of FMN2 leads to accelerated age-associated memory impairment

Next, we decided to explore the mechanisms by which FMN2-mediated phenotypes at a young age increase risk for late life dementia. We first confirmed our observation that 8-month-old \textit{Fmn2}$^{+/+}$ mice exhibit impaired memory formation (see Fig 1E) in an additional memory test, namely the hippocampus-dependent Morris water maze paradigm. There was no difference in the escape latency when comparing 3- versus 8-month-old wild-type mice (Fig 4A). However, 8-month-old \textit{Fmn2}$^{-/-}$ mice were significantly impaired when compared to age-matched wild-type mice (Fig 4B). This finding was confirmed in a probe test performed after 10 days of training. While 3- and 8-month-old wild-type mice showed a significant preference for the target quadrant, 8-month-old \textit{Fmn2}$^{-/-}$ mice were significantly impaired (Fig 4B). These data confirm that loss of \textit{Fmn2} accelerates age-associated memory impairment.
Figure 3.

Roberto Carlos Agis-Balboa et al
Linking psychiatric diseases to dementia

The EMBO Journal

Vol 36 | No 19 | 2017

© 2017 The Authors

Published online: August 2, 2017

The EMBO Journal
we decided to investigate the impact of FMN2 on cognitive decline in the presence of another risk factor for AD, namely amyloid deposition. To this end, we employed APPPS1-21 mice. We observed that 3-month-old APPPS1-21 mice subjected to the open-field test and the contextual fear conditioning paradigm showed explorative (Fig 4C) and freezing behavior that was similar to wild-type mice, suggesting that at 3 months of age APPPS1-21 mice show no defect in associative memory formation (Fig 4D). Thus, we reasoned that the analysis in 3-month-old mice would enable us to detect synergistic effects on memory impairment in Fmn2+/− and APPPS1-21 mice. To this end, we crossed Fmn2+/− mice with APPPS1-21 (APP) mice and tested memory function in animals at 3 months of age. As expected, brain weight was not affected (see Appendix Fig S2). Moreover, explorative behavior in the open-field test did not differ significantly amongst groups (Fig 4C). When subjected to the fear conditioning paradigm, neither 3-month-old Fmn2+/− nor APPPS1-21 mice showed impaired freezing behavior in comparison with control littersmates (Fig 4D). Freezing behavior was, however, significantly impaired in 3-month-old Fmn2+/−_APPPS-21 mice (Fig 4D). Next we assayed spatial memory in the Morris water maze paradigm. All groups were able to acquire spatial memory throughout the 8 days of training (Fig 4E). When subjected to the probe test, all groups except Fmn2+/−_APPPS-21 mice showed a significant preference for the target quadrant (Fig 4F). In conclusion, these data show that reduced levels of FMN2 further accelerate memory decline in a mouse model for aging and in a model for amyloid deposition.

**Loss of FMN2 accelerates age- and amyloid-induced deregulation of gene expression**

We have previously hypothesized that the various AD risk factors eventually cause aberrant gene expression, thereby contributing to the loss of homeostasis and memory decline (Sananbenesi & Fischer, 2009; Fischer, 2014). To test whether this hypothesis could help to explain how loss of Fmn2 at young age contributes to age-associative memory decline, we employed the hippocampal DG region for RNA-sequencing. First we compared gene expression levels in 3-month-old Fmn2+/− mice and age-matched control littersmates. In addition to the Fmn2 gene, we detected only 26 differentially expressed sequences (Fig 5A; Dataset EV1). Nevertheless, GO-term and functional pathway analysis identified “oxidative phosphorylation”—and especially subunits of the NADH dehydrogenase and ATPase—to be increased (Fig 5B and C). When we compared the gene expression in cognitively impaired 8-month-old Fmn2+/− mice to age-matched control littersmates, we detected 461 differentially expressed genes, of which the majority were down-regulated (Fig 5A). GO-term and pathway analysis revealed that the genes deregulated were linked to ribosome function, RNA splicing, Alzheimer’s disease, and oxidative phosphorylation (Fig 5D and F). While genes linked to oxidative phosphorylation were increased in 3-month-old mice, genes of the same complexes and especially genes encoding subunits of the NADH dehydrogenase, ATPase, and Cytochrome C reductase were all down-regulated in 8-month-old mice (Fig 5E, Dataset EV1). These data suggest that the susceptibility to develop PTSD-like phenotypes observed in 3-month-old Fmn2+/− mice is not accompanied by massive changes in gene expression, while memory impairment in 8-month-old Fmn2+/− mice correlates with substantial deregulation of transcriptome plasticity. The fact that the spliceosome appeared to be deregulated in 8-month-old Fmn2+/− mice is in line with recent data suggesting that during aging, synaptic plasticity genes are deregulated at the level of differential exon usage (Stilling et al., 2014b; Benito et al., 2015). Thus, we also analyzed differential exon usage. In 3-month-old Fmn2+/− mice, we detected 46 genes that showed altered differential exon usage when compared to 3-month-old control littersmates (Fig 5G, Dataset EV1). No significant pathways were identified. The same comparison was performed in 8-month-old Fmn2+/− and age-matched control mice and revealed 286 differentially expressed exons (Fig 5G). Further GO-term and pathways analysis showed that processes affected by differential splicing in 8-month-old Fmn2+/− mice are linked to synapse function (Fig 5H). In line with the gene expression data, we also observed that processes linked to energy metabolism and oxidative phosphorylation were deregulated (Fig 5H). In conclusion, these data indicate that the PTSD-like phenotypes observed in Fmn2+/− mice are not linked to substantial changes in gene expression, while aberrant gene expression is accelerated in the context of aging as an additional AD risk factor. To further substantiate this finding, we also analyzed gene expression in the DG of 3-month-old Fmn2+/−_APPPS-21. Comparing the gene expression in 3-month-old APPPS1-21 and age-matched wild-type control mice...
induce gene expression changes (Olson & Nordheim, 2010). In polymerization were found to signal to the nucleus and thereby actin dynamics, and it is interesting to note that changes in actin
Kreutz, 2009). FMN2 has been implicated with the regulation of amyloid deposition.

hypothesize that chronically low levels of FMN2 will eventually inflammation but is associated with deregulation of general cellular pathways represented inflammatory processes (Fig 5J). The top pathways affected in Fmn2+/- mice when compared to APPPS1-21 mice (Fig EV3A). When we analyzed the promoter regions of genes deregulated in 8-month-old Fmn2+/- mice for the presence of any consensus sequences, we observed a significant enrichment for the motifs “CCCCC” and “CCGGAAGC” which represents the ETS family of transcription factors (e.g., ELK) and the transcription factor specificity protein 1 (SP1), respectively (Fig EV3B). This is interesting, since SP1 and ELK have been linked to memory function and Alzheimer’s disease (Sananbenesi et al., 2002; Sung et al., 2013; Sztamari et al., 2013; Citron et al., 2015; Wei et al., 2016) and are amongst other kinases—activated via ERK1/2 (Bonello & Khachigian, 2004; Salim et al., 2007; Besnard et al., 2011; Kim et al., 2012). ERK1/2 is highly expressed in the mossy fiber pathway (Hu et al., 2004; Provenzano et al., 2014); has been linked to memory function, fear extinction, and Alzheimer’s disease (Sweatt, 2004; Fischer et al., 2002; Kim & Choi, 2015); interacts with the actin cytoskeleton; and translocates to the nucleus upon stimulation (Wang & Hatton, 2007; Berti & Seger, 2017). It is thus tempting to hypothesize that chronically reduced FMN2 levels cause subtle change to the actin cytoskeleton that will eventually alter ERK1/2/SP1/ELK signaling leading to revealed 50 differentially expressed genes, while 268 differentially expressed genes were detected comparing 3-month-old APPPS1-21 mice to age-matched Fmn2+/- APPPS1-21 mice (Fig 5I). The genes affected in 3-month-old APPPS1-21 mice were mainly linked to metabolic processes, suggesting that loss of Fmn2 does not accelerate Aβ-induced inflammation but is associated with deregulation of general cellular processes. In sum, these findings show that loss of FMN2 in young mice leaves the hippocampal transcriptome rather unaffected. However, chronically reduced FMN2 levels accelerate deregulation of hippocampal transcriptome plasticity in response to aging or amyloid deposition.

Since our data indicate that FMN2 is a synaptic protein, we hypothesize that chronically low levels of FMN2 will eventually affect pathways linked to synapse-to-nucleus signaling (Jordan & Kreutz, 2009). FMN2 has been implicated with the regulation of actin dynamics, and it is interesting to note that changes in actin polymerization were found to signal to the nucleus and thereby induce gene expression changes (Olson & Nordheim, 2010). In line with this, we observed that hippocampal actin dynamics were altered in Fmn2+/- mice (Fig EV3A). When we analyzed the promoter regions of genes deregulated in 8-month-old Fmn2+/- mice for the presence of any consensus sequences, we observed a significant enrichment for the motifs “CCCCC” and “CCGGAAGC” which represents the ETS family of transcription factors (e.g., ELK) and the transcription factor specificity protein 1 (SP1), respectively (Fig EV3B). This is interesting, since SP1 and ELK have been linked to memory function and Alzheimer’s disease (Sananbenesi et al., 2002; Sung et al., 2013; Sztamari et al., 2013; Citron et al., 2015; Wei et al., 2016) and are amongst other kinases—activated via ERK1/2 (Bonello & Khachigian, 2004; Salim et al., 2007; Besnard et al., 2011; Kim et al., 2012). ERK1/2 is highly expressed in the mossy fiber pathway (Hu et al., 2004; Provenzano et al., 2014); has been linked to memory function, fear extinction, and Alzheimer’s disease (Sweatt, 2004; Fischer et al., 2002; Kim & Choi, 2015); interacts with the actin cytoskeleton; and translocates to the nucleus upon stimulation (Wang & Hatton, 2007; Berti & Seger, 2017). It is thus tempting to hypothesize that chronically reduced FMN2 levels cause subtle change to the actin cytoskeleton that will eventually alter ERK1/2/SP1/ELK signaling leading to
aberrant gene expression. In line with this hypothesis, we observed that FMN2 and ERK1/2 interact and colocalize at the mossy fiber synapse (Fig EV3–F) and that levels of active ERK1/2, SP1, and ELK1 are reduced in 8-month-old Fmn2−/− mice (Fig EV3D). Although these data suggest one possible link between loss of FMN2 function and aberrant gene expression (Fig EV3G), certainly also other processes contribute to this phenotype. Irrespective of the multifactorial processes that link decreased FMN2 levels to aberrant gene expression, it is interesting to note that drugs aiming to state physiological gene expression such as inhibitors of histone-deacetylases (HDAC) were shown to improve learning behavior in mouse models for age-associated memory decline and amyloid deposition (Guan et al., 2011; Benito et al., 2010; Peleg et al., 2010; Govindarajan et al., 2011; Benito et al., 2015). Therefore, we wondered if HDAC inhibitors may also help to improve memory function in 8-month-old Fmn2−/− mice and in 3-month-old Fmn2−/−_APPPS-21 mice.

Vorinostat rescues memory impairment in aged Fmn2−/− and Fmn2−/−_APP mice

Vorinostat (SAHA) is an FDA-approved HDAC inhibitor with beneficial effect on memory function (Kilgore et al., 2010; Benito et al., 2015). Thus, we decided to test its effect in aged Fmn2−/− mice and in Fmn2−/−_APPPS-21 mice. First, we treated 7-month-old Fmn2−/− mice orally with Vorinostat (50 mg/kg) or placebo for 4 weeks. Explorative behavior measured in the open-field test was similar amongst groups (Fig 6A). Basal anxiety analyzed by comparing the center activity in the open field (Fig 6B) and by subjecting animals to the elevated plus maze test was also similar amongst groups (Fig 6C). Next we analyzed hippocampus-dependent associative memory in the contextual fear conditioning paradigm. Freezing behavior during the memory test was significantly increased in Vorinostat-treated Fmn2−/− mice (Fig 6D). We also analyzed hippocampus-dependent spatial learning in the water
mice treated with Vorinostat showed a significantly improved escape latency, indicative of improved spatial memory formation (Fig 6E). Swim speed was similar amongst groups (Fig 6F). We also tested the expression of selected genes linked to oxidative phosphorylation that were down-regulated in the DG of 8-month-old Fmn2−/− mice when compared to wild-type control littermates (see Fig 5). All selected genes were increased in the Vorinostat group when compared to placebo-treated Fmn2−/− mice (Fig 6G). HDAC inhibitors can affect gene expression by changing histone-acetylation. Reduced acetylation of histone 4 lysine 12 (H4K12ac) has been previously linked to age-associated memory decline (Guan et al., 2009; Peleg et al., 2010; Benito et al., 2015). In line with the gene expression data, we observed reduced H4K12ac in aged Fmn2−/− mice, which was, however, increased in mice treated with Vorinostat (Fig EV4). To further substantiate these findings, we performed a similar experiment in Fmn2−/− APPPS1-21 mice. Two-month-old Fmn2−/− APPPS1-21 mice were treated orally with either Vorinostat or placebo. Placebo-treated APP mice served as an additional control. Behavior in the open-field and elevated plus maze test did not differ amongst groups. However, similar to the findings in aged Fmn2−/− mice, we observed that Vorinostat treatment was able to ameliorate memory deficits, H4K12ac and gene expression in Fmn2−/− APPPS1-21 (Figs EV4 and EV5).

Discussion

Our study was inspired by the observation that young individuals suffering from psychiatric diseases such as PTSD have an increased risk to develop AD as they age (Yaffe et al., 2010; Burri et al., 2013; Weiner et al., 2013). We reasoned that one possible way to begin elucidating this phenomenon would be to select genes that have been implicated with age-associative memory decline and to test whether these genes may also play a role in the development of PTSD-like phenotypes, which we analyzed in mice via fear extinction as a commonly used and robust paradigm. Nevertheless, we like to reiterate that results from animal models of neuropsychiatric diseases have to be interpreted with care, and while impaired fear extinction in rodents may point to the mechanisms that underlie increased susceptibility for PTSD, it does not fully recapitulate the phenotypes observed in PTSD patients. We observed that deficits in fear extinction precede memory decline in Fmn2−/− mice, and moreover, Fmn2 expression was decreased in PTSD and AD patients.

Figure 6. Cognitive decline in 8-month-old Fmn2−/− mice is rescued by the HDAC inhibitor Vorinostat.

A The total distance traveled during a 5-min open-field exposure was similar amongst groups (Fmn2−/− placebo, n = 9, Fmn2−/− Vorinostat, n = 12).

B The time spent in the center and the corners during a 5-min open-field exposure was similar amongst groups (Fmn2−/− placebo, n = 9, Fmn2−/− Vorinostat, n = 12).

C The time spent in the open (o) and closed arms (c) or the center region (Ce) of an elevated plus maze was similar amongst groups (Fmn2−/− placebo, n = 7, Fmn2−/− Vorinostat, n = 10).

D Freezing behavior during the memory test was significantly increased in the Fmn2−/− Vorinostat group when compared to the placebo group (***P < 0.001, t-test; Fmn2−/− placebo, n = 8, Fmn2−/− Vorinostat, n = 9).

E Left panel: The escape latency in the water maze test was significantly improved in the Fmn2−/− Vorinostat group when compared to the placebo group (***P < 0.0001, two-way RM ANOVA, n = 10/group). Right panel: Swim speed was not altered amongst groups.

F Mice of the Fmn2−/− Vorinostat group spent significantly more time in the target quadrant (T) compared to the other quadrants (OQ). Please note the values for OQ are presented as average of all three other quadrants (***P < 0.0001, post hoc analysis, n = 10/group).

G Expression of selected genes that were down-regulated in 8-month-old Fmn2−/− mice was significantly increased in the dentate gyrus from mice of the Fmn2−/− Vorinostat group when compared to placebo (*P < 0.05; t-test, n = 4/group).

Data information: Error bars indicate SEM.
and decided to follow up on this novel observation. We found that Fmn2 is highly expressed in neurons of the mouse and human hippocampus and is especially enriched in the hippocampal mossy fiber pathway, where it is localized to pre-synaptic terminals. These data are in line with previous in situ hybridization findings showing that in the adult mouse brain Fmn2 expression is highest in the hippocampal dentate gyrus (Schumacher et al., 2004). Nevertheless, it is likely that posttranslational mechanisms contribute to the enrichment of FMN2 at the mossy fibers. Interestingly, loss of Fmn2 had no effect on LTP or LTD at the mossy fiber-CA3 synapse. Taking into account that LTP and LTD have been considered as molecular correlates of memory consolidation, these data are in agreement with the fact that young Fmn2 mutant mice have no deficit in the consolidation of new memories. However, depotentiation was impaired in Fmn2+/- mice. It is tempting to link this observation to the behavioral phenotypes. Hence, at the synaptic and the behavioral level, mice that lack Fmn2 at a young age are able to induce plasticity-related processes that are essential for information storage, but are impaired in modifying this information subsequently. These data are in line with previous studies, suggesting that depotentiation in the amygdala is required for fear extinction (Hong et al., 2009; Kim et al., 2009). The precise mechanisms by which loss of FMN2 affects depotentiation remain to be investigated. However, depotentiation has been linked to altered actin dynamics which in turn affects multiple synaptic processes such as vesicle trafficking (Galvez et al., 2016). We suggest that future research should test if such processes play a role in FMN2-mediated fear extinction. However, impaired depotentiation is certainly not the only process responsible for impaired fear extinction in Fmn2+/- mice.

A key observation of our study is that chronically reduced levels of Fmn2 accelerate age-associative memory decline. The fact that in young Fmn2-/- mice the formation of hippocampus-dependent memories is not affected suggests that memory decline observed during aging is most likely an indirect consequence of the molecular changes triggered by chronically reduced Fmn2 function. We hypothesize that such changes eventually lead to altered gene expression contributing to memory impairment. Indeed, we observed noticeable changes in hippocampal gene expression in 3-month-old Fmn2-/- mice, while loss of Fmn2 dramatically increases the number of deregulated genes during aging or in response to amyloid pathology. These data support our idea that AD risk factors synergistically drive aberrant gene expression and thereby eventually contribute to dementia (Fig 7). Importantly, neither amyloid deposition nor Fmn2 are likely to affect gene expression directly. While the precise mechanisms that couple FMN2-mediated defects in hippocampal function to deregulation of gene expression are likely multifactorial, it is interesting to note that stimuli which promote rearrangement of the actin cytoskeleton were found to induce gene expression changes (Olson & Nordheim, 2010). In line with this, we observe that loss of FMN2 affects actin dynamics which confirms previous data from other cellular systems (Pfender et al., 2011; Schuh, 2011; Montaville et al., 2016; Sahasrabudhe et al., 2016) and is in agreement with the fact that blocking actin dynamics in the hippocampus impairs fear extinction (Fischer et al., 2004). Alteration of actin dynamics has been associated with ERK1/2-mediated changes in gene expression (Wang & Hatton, 2007; Berti & Seger, 2017). Indeed, we found reduced ERK1/2 activity in Fmn2-/- mice. The finding that ERK1/2 activates the transcription factors ELK1 and SP1 is in line with our data showing that binding sites for these factors are enriched amongst the genes deregulated in aged Fmn2-/- mice (Fig EV3G). However, there are other processes linking synaptic plasticity to gene expression contributing to memory impairment. The fact that in young Fmn2-/- mice the formation of hippocampus-dependent memories is not affected suggests that memory decline observed during aging is most likely an indirect consequence of the molecular changes triggered by chronically reduced Fmn2 function. We hypothesize that such changes eventually lead to altered gene expression contributing to memory impairment. Indeed, we observed noticeable changes in hippocampal gene expression in 3-month-old Fmn2-/- mice, while loss of Fmn2 dramatically increases the number of deregulated genes during aging or in response to amyloid pathology. These data support our idea that AD risk factors synergistically drive aberrant gene expression and thereby eventually contribute to dementia (Fig 7). Importantly, neither amyloid deposition nor Fmn2 are likely to affect gene expression directly. While the precise mechanisms that couple FMN2-mediated defects in hippocampal function to deregulation of gene expression are likely multifactorial, it is interesting to note that stimuli which promote rearrangement of the actin cytoskeleton were found to induce gene expression changes (Olson & Nordheim, 2010). In line with this, we observe that loss of FMN2 affects actin dynamics which confirms previous data from other cellular systems (Pfender et al., 2011; Schuh, 2011; Montaville et al., 2016; Sahasrabudhe et al., 2016) and is in agreement with the fact that blocking actin dynamics in the hippocampus impairs fear extinction (Fischer et al., 2004). Alteration of actin dynamics has been associated with ERK1/2-mediated changes in gene expression (Wang & Hatton, 2007; Berti & Seger, 2017). Indeed, we found reduced ERK1/2 activity in Fmn2-/- mice. The finding that ERK1/2 activates the transcription factors ELK1 and SP1 is in line with our data showing that binding sites for these factors are enriched amongst the genes deregulated in aged Fmn2-/- mice (Fig EV3G). However, there are other processes linking synaptic plasticity to gene expression contributing to memory impairment. The fact that in young Fmn2-/- mice the formation of hippocampus-dependent memories is not affected suggests that memory decline observed during aging is most likely an indirect consequence of the molecular changes triggered by chronically reduced Fmn2 function. We hypothesize that such changes eventually lead to altered gene expression contributing to memory impairment. Indeed, we observed noticeable changes in hippocampal gene expression in 3-month-old Fmn2-/- mice, while loss of Fmn2 dramatically increases the number of deregulated genes during aging or in response to amyloid pathology. These data support our idea that AD risk factors synergistically drive aberrant gene expression and thereby eventually contribute to dementia (Fig 7). Importantly, neither amyloid deposition nor Fmn2 are likely to affect gene expression directly. While the precise mechanisms that couple FMN2-mediated defects in hippocampal function to deregulation of gene expression are likely multifactorial, it is interesting to note that stimuli which promote rearrangement of the actin cytoskeleton were found to induce gene expression changes (Olson & Nordheim, 2010). In line with this, we observe that loss of FMN2 affects actin dynamics which confirms previous data from other cellular systems (Pfender et al., 2011; Schuh, 2011; Montaville et al., 2016; Sahasrabudhe et al., 2016) and is in agreement with the fact that blocking actin dynamics in the hippocampus impairs fear extinction (Fischer et al., 2004). Alteration of actin dynamics has been associated with ERK1/2-mediated changes in gene expression (Wang & Hatton, 2007; Berti & Seger, 2017). Indeed, we found reduced ERK1/2 activity in Fmn2-/- mice. The finding that ERK1/2 activates the transcription factors ELK1 and SP1 is in line with our data showing that binding sites for these factors are enriched amongst the genes deregulated in aged Fmn2-/- mice (Fig EV3G). However, there are other processes linking synaptic plasticity to gene expression contributing to memory impairment. The fact that in young Fmn2-/- mice the formation of hippocampus-dependent memories is not affected suggests that memory decline observed during aging is most likely an indirect consequence of the molecular changes triggered by chronically reduced Fmn2 function. We hypothesize that such changes eventually lead to altered gene expression contributing to memory impairment. Indeed, we observed noticeable changes in hippocampal gene expression in 3-month-old Fmn2-/- mice, while loss of Fmn2 dramatically increases the number of deregulated genes during aging or in response to amyloid pathology. These data support our idea that AD risk factors synergistically drive aberrant gene expression and thereby eventually contribute to dementia (Fig 7). Importantly, neither amyloid deposition nor Fmn2 are likely to affect gene expression directly. While the precise mechanisms that couple FMN2-mediated defects in hippocampal function to deregulation of gene expression are likely multifactorial, it is interesting to note that stimuli which promote rearrangement of the actin cytoskeleton were found to induce gene expression changes (Olson & Nordheim, 2010). In line with this, we observe that loss of FMN2 affects actin dynamics which confirms previous data from other cellular systems (Pfender et al., 2011; Schuh, 2011; Montaville et al., 2016; Sahasrabudhe et al., 2016) and is in agreement with the fact that blocking actin dynamics in the hippocampus impairs fear extinction (Fischer et al., 2004). Alteration of actin dynamics has been associated with ERK1/2-mediated changes in gene expression (Wang & Hatton, 2007; Berti & Seger, 2017). Indeed, we found reduced ERK1/2 activity in Fmn2-/- mice. The finding that ERK1/2 activates the transcription factors ELK1 and SP1 is in line with our data showing that binding sites for these factors are enriched amongst the genes deregulated in aged Fmn2-/- mice (Fig EV3G). However, there are other processes linking synaptic plasticity to gene expression contributing to memory impairment. The fact that in young Fmn2-/- mice the formation of hippocampus-dependent memories is not affected suggests that memory decline observed during aging is most likely an indirect consequence of the molecular changes triggered by chronically reduced Fmn2 function. We hypothesize that such changes eventually lead to altered gene expression contributing to memory impairment. Indeed, we observed noticeable changes in hippocampal gene expression in 3-month-old Fmn2-/- mice, while loss of Fmn2 dramatically increases the number of deregulated genes during aging or in response to amyloid pathology. These data support our idea that AD risk factors synergistically drive aberrant gene expression and thereby eventually contribute to dementia (Fig 7). Importantly, neither amyloid deposition nor Fmn2 are likely to affect gene expression directly.
expression (Jordan & Kreutz, 2009) that likely also contribute to a loss of transcriptional homeostasis. The view that disturbed transcriptome plasticity causatively contributes to memory loss is supported by our observation that the HDAC inhibitor Vorinostat reinstates hippocampal memory formation in aged Fmn2+/− mice and also in APPPS1-21 mice that lack Fmn2.

In conclusion, our data provide insight to the molecular mechanisms by which neuropsychiatric diseases at a young age lead to an increased risk for dementia when individuals age. We suggest that our experimental approach should be applied to additional genes and environmental factors implicated with PTSD or other neuropsychiatric diseases. Our data also provide a more general insight of how the various AD risk factors (in our case, FMN2-mediated PTSD-like phenotypes, amyloid deposition, and aging) contribute to dementia. Targeting transcriptome plasticity would thus be a very suitable therapeutic approach that is independent of the precise knowledge to the upstream pathological events (Fig 7). In line with this, we show that the HDAC inhibitor Vorinostat reinstates hippocampal memory formation in aged Fmn2+/− mice and also in APPPS1-21 mice that lack Fmn2. Of course, we cannot exclude that the memory enhancing effect of Vorinostat also involves processes not directly related to gene expression. It is, however, interesting to note that HDAC inhibitors are also discussed as a novel therapeutic avenue to treat PTSD (Whittle & Singewald, 2014). In fact, Vorinostat not only improves memory function, but also facilitates extinction of fear memories (Whittle et al., 2013), a finding we could confirm in our paradigm (see Appendix Fig S3). Our data therefore indicate that it might be possible to develop therapeutic strategies for PTSD patients that at the same time lower the risk to develop Alzheimer’s disease, a line of research that should also be taken into consideration for other neuropsychiatric diseases.

Materials and Methods

For detailed description of methods, see the Appendix Supplementary Methods.

Animals and human tissue

Male mice were housed under standard conditions with free access to food and water. All experiments were carried out in accordance with the animal protection law and were approved by the District Government of Germany. Fmn2+/− and APPPS-21 mice have been described before (Leader et al., 2002; Radde et al., 2006). Three-, 12-, and 16-month-old wild-type mice were obtained from Janvier Labs. Post-mortem hippocampal tissue from AD patients and controls was obtained with ethical approval from the Alzheimer’s disease Research Center Brain bank at Massachusetts General Hospital, Boston, MA, and from Brigham & Women’s Hospital Autopsy Service, Boston, MA, USA. Samples were matched for age and post-mortem delay. AD patients Braak and Braak stage were 3–5. EDTA blood samples from PTSD patients and controls were from the Ramstein cohort described previously (Zieler et al., 2007). These individuals were exposed to the trauma of the air show catastrophe in Ramstein, Germany, 1988. We employed nine age- and gender-matched controls (46.38 ± 4.363 years of age) and seven PTSD patients (52.29 ± 5.515 years of age). Patients were diagnosed according to DSM IV (SKID-I; Wittchen et al., 1997). Symptom severity was measured using the German versions of the clinician-administered PTSD scale [CAPS] (Schnyder & Moergelli, 2002; mean = 40.0, SD = 22.9; > 40 moderate PTSD), the Posttraumatic Stress Diagnostic Scale [PDS] (Foa et al., 1993; mean = 18.8, SD = 11.1; > 20 moderate to severe PTSD), the 22-item Impact of Event Scale Revised [IES-R] (Horowitz et al., 1979; mean = 48.0, SD = 18.7), and the Questionnaire on Dissociative Symptoms [FDS] (Freyberger et al., 1999; mean = 9.8, SD = 8.5; > 8.4 dissociative symptoms). To characterize possible comorbidity with a depressive disorder, the German version of the Beck Depression Inventory [BDI] (Hautzinger, 1991) was performed (mean = 14.3, SD = 9.1; > 18 relevant depression). None of the patients had been taking psychoactive drugs on a regular basis 3 months prior to the study. All experiments were approved by the local ethical committees, and tissue/blood samples were obtained upon informed consent.

Behavior analysis

Mice were subjected to a series of behavioral tests as described before (Kerimoglu et al., 2013).

Cannulation and siRNA injection

Intra-hippocampal injections were performed as described previously (Bahari-Javan et al., 2012).

Statistical analysis

Unless specifically mentioned otherwise, data were analyzed by unpaired Student’s t-test, two tailed t-test, Bonferroni test for multiple comparisons, or one and two-way and ANOVA (analysis of variance) when appropriate. Errors are displayed as standard error of mean (SEM). Unless otherwise stated, analysis was performed using GraphPad Prism.

Gene expression

Analysis of RNA-sequencing has been described before (Stilling et al., 2014a). Data have been deposited to GEO database: GSE100070.

Expanded View for this article is available online.

Acknowledgements

This work was supported by the following third party funds to AF: DFG research group KFO241/PsyCourse F081-4 and F081 11-1, DFG project 179/1-1/2013, an ERC consolidator grant (DEPICODE 648898), and the BMBF project Integrate; PF was supported by the KFO241/PsyCourse Project FA 241/16-1 (PF); FS was supported by the DFG grant SA 1005/2-1. RCA8 was supported by a Ramdán y Cajal grant (RyC-2014-15246) and by Galicia Innovation Agency (IN607D-2016/003). We thank George Lu (University of Michigan) for proofreading the manuscript.

Author contributions

RCA-B performed most of the experiments; PP, NR, and CM performed electrophysiological measurements; CK, EB, GJ, and SB performed gene expression analysis; MG and SB-J helped with behavioral experiments related to siRNA
injections; ID provided post-mortem human brain tissue; AJ, AS, and PF provided blood samples from PTSD patients; PA2, JCP, and EBB performed experiments in human neuronal progenitor cells; AF and FS designed and coordinated the experiments and wrote the manuscript. MD generated FMN2-EGFP mice.

Conflict of interest
The authors declare that they have no conflict of interest.

References


memory deficits in a mouse model of Alzheimer’s disease.

Neuropsychopharmacology 35: 870 – 880


License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.